Kenneth has made over 7 trades of the Sangamo Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 177,935 units of SGMO stock worth $1,085,404 on 28 June 2018.
The largest trade he's ever made was exercising 177,935 units of Sangamo Therapeutics Inc stock on 28 June 2018 worth over $1,085,404. On average, Kenneth trades about 10,117 units every 27 days since 2017. As of 28 June 2018 he still owns at least 293,336 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Kenneth Hillan stock trades at the bottom of the page.
Dr. Kenneth J. Hillan serves as Director of the Company. Since 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, the consumer genetics and research company, leading a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. Previously, Dr. Hillan held leadership roles in the biotechnology industry. He served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair; Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech's Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. From 2011 to 2017, he was Chief Executive Officer of Achaogen, Inc., where he was also a member of the Board of Directors. He has also served on the Board of Directors of Zymeworks since February 2017, and was a member of the Board of Directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG. Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a inventor on almost 50 issued patents.
Kenneth Hillan is 58, he's been the Director of Sangamo Therapeutics Inc since 2020. There are 3 older and 12 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.
Kenneth's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND, CA, 94084.
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp és Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: